Scott Nightingale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Scott Nightingale has a total of 238 co-authors. Here are the top co-authors by number of shared publications:
- Michael Jonathon Coffey
School of Clinical Medicine, Discipline of Paediatrics & Child Health, Randwick Clinical Campus, UNSW Medicine & Health, University of New South Wales
10 shared publications - Chee Yee Ooi
Molecular and Integrative Cystic Fibrosis (miCF) Research Centre UNSW Sydney Sydney New South Wales Australia
9 shared publications Chee Y. Ooi
3 shared publicationsJoerg Mattes
Priority Research Centre GrowUpWell University of Newcastle and HMRI
3 shared publications- Vicky Lee Ng
Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children University of Toronto Toronto Ontario Canada
3 shared publications - Adam M. Collison
The University of Newcastle
2 shared publications
Latest Publications
- Open Access
Biophysical dissection of SOX18/NR2F2 transcriptional antagonism reveals mechanisms of venous differentiation and drug action in vascular malformation
Translating genomic discoveries into therapies for rare genetic disorders remains a significant challenge, particularly for variants of unknown significance (VUS) where molecular mechanisms are unclear. This is particularly relevant in vascular malformations, where venous differentiation remains poorly understood, and the role of transcription factors in specifying venous identity is only beginning to be elucidated. Here, we combine live-cell single-molecule imaging with genomics-based approaches to uncover a biophysical mechanism of transcription factor antagonism that underpins venous identity. We show that SOX18 and NR2F2 antagonistically co-regulate venous differentiation through dynamic feedback between their nuclear populations. This interaction is disrupted in vascular malformation syndrome caused by a de novo heterozygous NR2F2 mutation, presenting with aberrant vascular integrity and bleeding. Treatment with an FDA-approved drug—known to inhibit SOX18—led to marked clinical improvement in the proband. To dissect the molecular mechanism underlying this mutation and the drug response, we used human embryonic stem cells (hESCs) engineered to carry the proband’s NR2F2 variant. These cells exhibited impaired hESC to venous differentiation with no effect on artery EC differentiation. In silico modelling and live-cell molecular imaging revealed that the NR2F2 variant is hyper-mobile, fails to form homodimers, and cannot recruit SOX18, thereby disrupting a critical transcriptional antagonism that underpins venous endothelial identity. We demonstrate that targeted pharmacological inhibition of SOX18 restores this regulatory balance in hESC-derived venous endothelial cells, rescuing both gene expression and NR2F2 binding dynamics at the single-molecule level. Together, this study uncovers a biophysical mechanism of transcription factor antagonism that governs venous differentiation and offers a framework for developing targeted therapies for rare vascular malformations.
Open AccessBiophysical dissection of SOX18/NR2F2 transcriptional antagonism reveals mechanisms of venous differentiation and drug action in vascular malformation
Translating genomic discoveries into therapies for rare genetic disorders remains a significant challenge, particularly for variants of unknown significance (VUS) where molecular mechanisms are unclear. This is particularly relevant in vascular malformations, where venous differentiation remains poorly understood, and the role of transcription factors in specifying venous identity is only beginning to be elucidated. Here, we combine live-cell single-molecule imaging with genomics-based approaches to uncover a biophysical mechanism of transcription factor antagonism that underpins venous identity. We show that SOX18 and NR2F2 antagonistically co-regulate venous differentiation through dynamic feedback between their nuclear populations. This interaction is disrupted in vascular malformation syndrome caused by a de novo heterozygous NR2F2 mutation, presenting with aberrant vascular integrity and bleeding. Treatment with an FDA-approved drug—known to inhibit SOX18—led to marked clinical improvement in the proband. To dissect the molecular mechanism underlying this mutation and the drug response, we used human embryonic stem cells (hESCs) engineered to carry the proband’s NR2F2 variant. These cells exhibited impaired hESC to venous differentiation with no effect on artery EC differentiation. In silico modelling and live-cell molecular imaging revealed that the NR2F2 variant is hyper-mobile, fails to form homodimers, and cannot recruit SOX18, thereby disrupting a critical transcriptional antagonism that underpins venous endothelial identity. We demonstrate that targeted pharmacological inhibition of SOX18 restores this regulatory balance in hESC-derived venous endothelial cells, rescuing both gene expression and NR2F2 binding dynamics at the single-molecule level. Together, this study uncovers a biophysical mechanism of transcription factor antagonism that governs venous differentiation and offers a framework for developing targeted therapies for rare vascular malformations.
- 16 February 2023
- Published by Wiley in Medical Journal of Australia
- Vol. 218 (5) , 229-230
Direct‐acting antiviral treatments in Australia for children with chronic hepatitis C virus infection
- 16 February 2023
- Published by Wiley in Medical Journal of Australia
- Vol. 218 (5) , 229-230
Direct‐acting antiviral treatments in Australia for children with chronic hepatitis C virus infection
- Open Access
- 27 June 2022
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 58 (11) , 2106-2108
Severe Graves' disease presenting with hepatic dysfunction in a 2‐year‐old child
- 27 June 2022
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 58 (11) , 2106-2108
Open AccessSevere Graves' disease presenting with hepatic dysfunction in a 2‐year‐old child
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Pediatric Surgery Case Reports
- Vol. 64
Bowel scintigraphy identifies segmental dysmotility prior to stoma closure
- 1 January 2021
- Published by Elsevier in Journal of Pediatric Surgery Case Reports
- Vol. 64
Open AccessBowel scintigraphy identifies segmental dysmotility prior to stoma closure
- 29 May 2020
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 56 (11) , 1724-1730
Functional gastrointestinal disorders in children: What is new?
Abdominal pain‐predominant functional gastrointestinal disorders encompass a group of chronic conditions featuring abdominal pain where no serious gastrointestinal or intra‐abdominal pathology is present. The Rome IV classification system defines and categorises this group based on symptomatology as: functional dyspepsia, irritable bowel syndrome, functional abdominal pain – not otherwise specified and abdominal migraine. These conditions can impact the functioning of the child and family significantly and are challenging to manage. Although the causes of these conditions are not clear, recent years have seen an improved understanding of underlying pathophysiology and identification of effective management options for these conditions.
- 29 May 2020
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 56 (11) , 1724-1730
Functional gastrointestinal disorders in children: What is new?
Abdominal pain‐predominant functional gastrointestinal disorders encompass a group of chronic conditions featuring abdominal pain where no serious gastrointestinal or intra‐abdominal pathology is present. The Rome IV classification system defines and categorises this group based on symptomatology as: functional dyspepsia, irritable bowel syndrome, functional abdominal pain – not otherwise specified and abdominal migraine. These conditions can impact the functioning of the child and family significantly and are challenging to manage. Although the causes of these conditions are not clear, recent years have seen an improved understanding of underlying pathophysiology and identification of effective management options for these conditions.
- Open Access
- 20 June 2019
- Published by Wolters Kluwer Health in Hepatology
- Vol. 71 (1) , 31-43
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection
Currently, the only approved hepatitis C virus (HCV) treatment for children aged Conclusion: Sofosbuvir plus ribavirin was well tolerated and highly effective in children aged 3 to <12 years with chronic HCV genotype 2 or 3 infection.
- 20 June 2019
- Published by Wolters Kluwer Health in Hepatology
- Vol. 71 (1) , 31-43
Open AccessSofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection
Currently, the only approved hepatitis C virus (HCV) treatment for children aged Conclusion: Sofosbuvir plus ribavirin was well tolerated and highly effective in children aged 3 to <12 years with chronic HCV genotype 2 or 3 infection.
- 26 February 2019
- Published by Springer Nature in Pediatric Surgery International
- Vol. 35 (5) , 569-574
Adolescent gallstones—need for early intervention in symptomatic idiopathic gallstones
Currently, there is a paucity of the literature describing the natural history of cholelithiasis (CL) and choledocholithiasis (CDL) in adolescent children. This study aims to analyse the changing demographics of paediatric and adolescent gallstones.
- 26 February 2019
- Published by Springer Nature in Pediatric Surgery International
- Vol. 35 (5) , 569-574
Adolescent gallstones—need for early intervention in symptomatic idiopathic gallstones
Currently, there is a paucity of the literature describing the natural history of cholelithiasis (CL) and choledocholithiasis (CDL) in adolescent children. This study aims to analyse the changing demographics of paediatric and adolescent gallstones.
- 9 January 2019
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 55 (9) , 1063-1069
Functional gastrointestinal disorders in children and adolescents: Knowledge, practice and attitudes of Australian paediatricians
Aim To investigate paediatricians' understanding of, and approaches to, the diagnosis and treatment of functional abdominal pain (FAP) and irritable bowel syndrome (IBS) in children. Methods This study used an electronic survey of doctors subscribing to a popular Australian‐based paediatrics email forum. Responses about investigation and management in two clinical vignettes were correlated with respondent demographic data, practice setting, attitudes and knowledge. Results The 327 respondents were mostly female (60.3%), aged P < 0.05), although most acknowledged they would not be helpful. Most (70.5%) believed that families are unlikely to accept an FAP diagnosis without investigations requested. Fewer than 1 of 3 were aware of clear evidence for the effective therapy of FAP or IBS, although awareness did not influence management options selected. Two‐thirds of respondents believe that FAP is a psychological rather than a medical problem, while few (8.8%) believe the same about IBS (P < 0.001). Parental pressure to find an immediate cure was cited as the most frequent challenge to successful management in both FAP (86.6%) and IBS (75.9%). Conclusions Awareness of the Rome criteria was associated with greater confidence in diagnosing FAP and IBS. Attitudes to FAP and IBS being diagnoses of exclusion are prevalent among paediatricians and associated with more investigations requested. There is a lack of awareness of evidence‐based therapies for FAP and IBS.
- 9 January 2019
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 55 (9) , 1063-1069
Functional gastrointestinal disorders in children and adolescents: Knowledge, practice and attitudes of Australian paediatricians
Aim To investigate paediatricians' understanding of, and approaches to, the diagnosis and treatment of functional abdominal pain (FAP) and irritable bowel syndrome (IBS) in children. Methods This study used an electronic survey of doctors subscribing to a popular Australian‐based paediatrics email forum. Responses about investigation and management in two clinical vignettes were correlated with respondent demographic data, practice setting, attitudes and knowledge. Results The 327 respondents were mostly female (60.3%), aged P < 0.05), although most acknowledged they would not be helpful. Most (70.5%) believed that families are unlikely to accept an FAP diagnosis without investigations requested. Fewer than 1 of 3 were aware of clear evidence for the effective therapy of FAP or IBS, although awareness did not influence management options selected. Two‐thirds of respondents believe that FAP is a psychological rather than a medical problem, while few (8.8%) believe the same about IBS (P < 0.001). Parental pressure to find an immediate cure was cited as the most frequent challenge to successful management in both FAP (86.6%) and IBS (75.9%). Conclusions Awareness of the Rome criteria was associated with greater confidence in diagnosing FAP and IBS. Attitudes to FAP and IBS being diagnoses of exclusion are prevalent among paediatricians and associated with more investigations requested. There is a lack of awareness of evidence‐based therapies for FAP and IBS.
- 1 October 2018
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 67 (4) , E83-E85
Endoscopic Treatment of Duodenal Web in Association With Annular Pancreas in an Infant
- 1 October 2018
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 67 (4) , E83-E85
Endoscopic Treatment of Duodenal Web in Association With Annular Pancreas in an Infant
- 21 May 2018
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 30 (9) , e13371
Variants in ACTG2 underlie a substantial number of Australasian patients with primary chronic intestinal pseudo‐obstruction
Background: Primary chronic intestinal pseudo‐obstruction (CIPO) is a rare, potentially life‐threatening disorder characterized by severely impaired gastrointestinal motility. The objective of this study was to examine the contribution of ACTG2, LMOD1, MYH11, and MYLK mutations in an Australasian cohort of patients with a diagnosis of primary CIPO associated with visceral myopathy.Methods: Pediatric and adult patients with primary CIPO and suspected visceral myopathy were recruited from across Australia and New Zealand. Sanger sequencing of the genes encoding enteric gamma‐actin (ACTG2) and smooth muscle leiomodin (LMOD1) was performed on DNA from patients, and their relatives, where available. MYH11 and MYLK were screened by next‐generation sequencing.Key results: We identified heterozygous missense variants in ACTG2 in 7 of 17 families (~41%) diagnosed with CIPO and its associated conditions. We also identified a previously unpublished missense mutation (c.443C>T, p.Arg148Leu) in one family. One case presented with megacystis‐microcolon‐intestinal hypoperistalsis syndrome in utero with subsequent termination of pregnancy at 28 weeks' gestation. All of the substitutions identified occurred at arginine residues. No likely pathogenic variants in LMOD1, MYH11, or MYLK were identified within our cohort.Conclusions and inferences: ACTG2 mutations represent a significant underlying cause of primary CIPO with visceral myopathy and associated phenotypes in Australasian patients. Thus, ACTG2 sequencing should be considered in cases presenting with hypoperistalsis phenotypes with suspected visceral myopathy. It is likely that variants in other genes encoding enteric smooth muscle contractile proteins will contribute further to the genetic heterogeneity of hypoperistalsis phenotypes.
- 21 May 2018
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 30 (9) , e13371
Variants in ACTG2 underlie a substantial number of Australasian patients with primary chronic intestinal pseudo‐obstruction
Background: Primary chronic intestinal pseudo‐obstruction (CIPO) is a rare, potentially life‐threatening disorder characterized by severely impaired gastrointestinal motility. The objective of this study was to examine the contribution of ACTG2, LMOD1, MYH11, and MYLK mutations in an Australasian cohort of patients with a diagnosis of primary CIPO associated with visceral myopathy.Methods: Pediatric and adult patients with primary CIPO and suspected visceral myopathy were recruited from across Australia and New Zealand. Sanger sequencing of the genes encoding enteric gamma‐actin (ACTG2) and smooth muscle leiomodin (LMOD1) was performed on DNA from patients, and their relatives, where available. MYH11 and MYLK were screened by next‐generation sequencing.Key results: We identified heterozygous missense variants in ACTG2 in 7 of 17 families (~41%) diagnosed with CIPO and its associated conditions. We also identified a previously unpublished missense mutation (c.443C>T, p.Arg148Leu) in one family. One case presented with megacystis‐microcolon‐intestinal hypoperistalsis syndrome in utero with subsequent termination of pregnancy at 28 weeks' gestation. All of the substitutions identified occurred at arginine residues. No likely pathogenic variants in LMOD1, MYH11, or MYLK were identified within our cohort.Conclusions and inferences: ACTG2 mutations represent a significant underlying cause of primary CIPO with visceral myopathy and associated phenotypes in Australasian patients. Thus, ACTG2 sequencing should be considered in cases presenting with hypoperistalsis phenotypes with suspected visceral myopathy. It is likely that variants in other genes encoding enteric smooth muscle contractile proteins will contribute further to the genetic heterogeneity of hypoperistalsis phenotypes.